glp 1 cardiovascular disease and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Cardiovascular disease continuum-GLP-1 action. Adapted

The claimant of the August 2023 lawsuit reported excessive, prolonged vomiting that caused her to lose some of her teeth

Other types of GLP-1 agonists include dulaglutide (Trulicity), liraglutide (Saxenda), and tirzepatide (Zepbound and Mounjaro), whose manufacturers are also facing lawsuits

The cardiovascular outcomes suggest that GLP-1 therapy offers systemic health benefits beyond simple calorie restriction, making these medications attractive for overall metabolic health even in the absence of diabetes

Willow at a Glance: Cost, Medications, and Telehealth Model 3

When severe symptoms dont respond to diet, medication may be an option